Pure 99% Orforglipron Powder

Orforglipron is a synthetic small-molecule compound produced through controlled chemical synthesis and supplied as a solid research material for laboratory investigation. Unlike peptide-based compounds, Orforglipron is a non-peptide heterocyclic molecule designed for use in experimental biochemical research environments. The encapsulated format serves solely as a physical containment and presentation method and does not imply any route of administration or intended method of use. Orforglipron is intended exclusively for controlled in-vitro laboratory research conducted by qualified professionals investigating synthetic small-molecule compounds.

Product Name:

Orforglipron (Encapsulated Solid)

Chemical Information:

Chemical Name: Orforglipron

Alternate Identifier: LY3502970

Molecular Formula: C₄₈H₄₈F2N₁₀O₅

Molecular Weight: ~886.95 g/mol

Compound Class: Synthetic small-molecule research compound

Chemical Type: Non-peptide heterocyclic small molecule

Molecular Structure

Regulation of blood glucose (anti-diabetic activity) It enhances glucose-dependent insulin secretion from pancreatic beta cells only when blood sugar is elevated. It suppresses glucagon release from alpha cells to reduce hepatic glucose production. This effect lowers fasting and postprandial blood glucose without causing a high risk of hypoglycemia. It is developed for the treatment of type 2 diabetes mellitus.

Appetite suppression and weight reduction By activating GLP‑1 receptors in the hypothalamic appetite center, it reduces food cravings, lowers calorie intake and prolongs stomach emptying time. It effectively reduces body weight and body fat mass in obese subjects. This is its primary researched application for obesity management.

Improvement of metabolic disorders The compound improves insulin sensitivity in peripheral tissues including liver and skeletal muscle. It helps reduce visceral fat, lower triglyceride levels and improve overall metabolic profiles.

Cardiometabolic protective effects Preclinical studies demonstrate that long-term GLP‑1R activation can alleviate oxidative stress and low-grade inflammation. Orforglipron shows potential benefits for reducing cardiovascular risk factors related to obesity and diabetes.

Additional Key Pharmacological Advantages

Small-molecule chemical structure enables excellent oral absorption, eliminating the need for subcutaneous injection.

High receptor selectivity; it has minimal binding activity against other peptide receptors, which cuts down off-target side effects.

Favorable pharmacokinetic profile with long half-life, supporting once-daily oral dosing.

Disclaimer

Orforglipron powder is strictly for laboratory preclinical research only. It is still under clinical trials and has not obtained marketing approval as a finished drug. No self-administration is permitted.

In-vitro evaluation of synthetic small-molecule behavior in biochemical or molecular assay systems

Laboratory investigation of structure–property relationships of heterocyclic research compounds

Analytical method development involving experimental non-peptide small-molecule materials

Comparative research involving structurally related synthetic molecules under controlled laboratory conditions

1. General Administration Rule

Route: Oral administration, once daily, with or without meals.

Dose escalation: Maintain each dose level for at least 4 weeks (30 days) before dose increase to minimize gastrointestinal side effects.

Dose reduction: Lower the dose if patients develop persistent nausea, vomiting or diarrheafoundayo.lilly.com.

2. Phase 3 Dosing for Obesity (ATTAIN Trials)

Stepwise Escalation Schedule

Initial starting dose: 1 mg once daily (Week 1–4)

Second tier: 3 mg once daily (Week 5–8)

Intermediate tier: 6 mg once daily (Week 9–12)

Mid maintenance dose: 12 mg once daily

High maintenance dose: 24 mg once daily

Maximum clinical trial dose: 36 mg once dailyEli Lilly and Company

Common maintenance doses for weight loss:

Moderate weight loss target: 12 mg per day

Max weight loss target: 36 mg per day

3. Phase 3 Dosing for Type 2 Diabetes (ACHIEVE Trials)

Same gradual dose titration starting at 1 mg daily, stepping up every 4 weeks. Approved trial maintenance doses:

Low glycemic control dose: 3 mg once daily

Standard therapeutic dose: 12 mg once daily

Max glycemic + weight loss dose: 36 mg once dailyEli Lilly and Company

4. FDA Approved Finished Tablet Dosage (Foundayo)

For reference of formulated drug strength: Titration sequence: 0.8 mg → 2.5 mg → 5.5 mg → 9 mg → 14.5 mg → maximum 17.2 mg once daily Each dose level is held for a minimum of 30 days before upward titration.

5. Dosage Adjustment for Special Populations

Mild to moderate hepatic or renal impairment: No dose modification required in clinical studies.

Elderly patients (≥65 years): Initiate at the lowest starting dose and slow the titration speed.

Patients with pre-existing gastrointestinal disease: Stay on lower maintenance doses to reduce adverse reactions.

6. Preclinical Animal Dosage (Reference for Bulk Powder Testing)

Rodent oral dose range: 1–15 mg/kg body weight daily.

Raw orforglipron crystalline powder cannot be directly used for human oral dosing due to poor bioavailability without formulation technology.

This agent remains under clinical development; bulk API powder is limited to pharmaceutical R&D only.

Do not co-administer with other GLP‑1 receptor agonists to avoid overlapping toxicity.

1. Most Common Adverse Reactions (Mild to Moderate, Dose-Dependent)

These gastrointestinal reactions occur mostly during the dose escalation period and gradually ease after the body adapts.

Nausea: The most frequent symptom, incidence ranges from 29% to 36% in medium and high-dose groups.

Constipation, diarrhea, vomiting: Higher incidence with daily oral dosing compared with injectable GLP‑1 peptides.

Indigestion, abdominal bloating, acid reflux, flatulence, upper stomach pain.

Other mild reactions: headache, fatigue, mild loss of appetite.

Most GI symptoms resolve within several weeks if the dose is increased slowly. Roughly 5%–8% of participants stop treatment due to persistent digestive discomfort.

2. Less Frequent Systemic Side Effects

Tachycardia: Slight increase in resting pulse rate, usually asymptomatic.

Mild hypotension: Higher risk in patients taking antihypertensive medicines simultaneously.

Transient dehydration caused by vomiting and diarrhea, which may trigger temporary renal function changes.

Hair thinning (sporadic cases reported in long-term trials)foundayo.lilly.com.

Mild hypoglycemia risk when combined with insulin or sulfonylurea diabetes drugs; no obvious hypoglycemia when used alone.

3. Rare but Serious Adverse Events (Class Risk for GLP‑1 Receptor Agonists)

Acute pancreatitis: Rare cases reported. Patients with persistent severe upper abdominal pain should discontinue use immediately.

Gallbladder disorders: Cholelithiasis and acute cholecystitis may occur with rapid weight loss.

Acute kidney injury: Secondary to severe vomiting, diarrhea and fluid loss.

Thyroid tumor risk: GLP‑1 agonists carry a theoretical risk of medullary thyroid carcinoma. This agent is contraindicated for patients with personal or family history of thyroid neoplasms.

No confirmed cases of severe allergic reaction, retinal damage or ischemic neuropathy in large clinical trials.

4. Dose Correlation

Low dose (1–6 mg daily): Only mild nausea and constipation; very low discontinuation rate.

Medium dose (12 mg daily): Balanced efficacy and tolerability, the preferred maintenance dose.

High dose (24–36 mg daily): Higher rates of vomiting and GI distress.

5. Special Population Warnings

Patients with chronic gastritis, IBS or peptic ulcer disease have worsened gastrointestinal intolerance.

Pregnant or breastfeeding individuals should avoid administration.

Patients with renal or hepatic impairment need slower dose titration and close monitoring.

Do not combine with other GLP‑1 agonists, which will drastically amplify side effects.

Other Nootropics Raw Material Also Available

Delivery Time:Around 3-5 workdays after your payment.

Package:1kg/aluminium foil bag;25Kgs in fiber-drums with two-plastic bags inside

Net Weight:25kgs/Drum/Gross Weight:28kgs/Drum

Drum Size & Volume:I.D.42cm × H52cm,0.08 m³/Drum

Storage:Stored in dry and cool place,keep away from strong light and heat.

Shelf Life:Two years when properly stored.

Hot Tags: pure 99% orforglipron powder, China pure 99% orforglipron powder manufacturers, suppliers, factory, Pantethine for Cardiovascular Health, Pantethine for Fatty Acid Metabolism, Pharmaceutical Pantethine Powder, Tianeptine Sodium Salt for Anxiety Relief, Yohimbine Hydrochloride Chemical, Zinc Bacitracin for Animal Health